VALBIOTIS SA: Valbiotis announces launch of operations in Asia

Valbiotis announces launch of operations in Asia

• The Chinese joint venture, 49% owned by Valbiotis and 51% by Aika, is now fully operational, as is its Hong Kong subsidiary
• Initial orders confirmed ahead of commercialization in China and Hong Kong starting in the second half of 2026
• Partnerships established with leading Chinese cross-border e-commerce platforms
• Parallel rollouts planned across other Asian markets

Next Event:

Webinar for Individual Shareholders: Wednesday, March 25 at 6:00 pm

To register or access the webinar

Login Link

La Rochelle, March 19, 2026 (5:40 pm CEST) – Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible), a French laboratory specializing in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life, announces the launch of its operations in Asia, in line with the timeline set out in the strategic agreement signed with the Chinese group Aika on November 17, 2025. 

Following administrative procedures initiated with the Chinese authorities, the joint venture was officially approved by the relevant authorities on March 10, 2026, in accordance with the terms set out in the agreements between Valbiotis and the Aika Group (Press Release of November 17, 2025).

Officially named "Hangzhou Valbiotis Life Health Technology Co. Ltd.", the newly established joint venture, dedicated to the commercialization of the ValbiotisPRO® product range, is structured as follows:

• 49% owned by Valbiotis, through the contribution of two licenses on its patents and exclusive trademarks in the territories covered by the agreement, relating to the active substances Lipidrive® (Cholesterol), Totum-63® (Metabolic Health), Tensodrive® (Cardio-circulation) and Steadrive® (TOTUM-448, currently in clinical development)
• 51% owned by Aika, through a cash contribution enabling the joint venture to benefit from €3M in initial cash at inception.

As a reminder, the joint venture will also benefit from an additional €2M in shareholder funding from the Aika Group, as well as potential local financing arrangements to support its working capital requirements.

Commercial Launch via CBEC Platforms

Now fully operational, the joint venture will begin marketing Valbiotis products in mainland China and Hong Kong through the cross-border e-commerce (CBEC) channel.

This commercialization will be carried out through the Hong Kong subsidiary, which is already operational and has already planned collaborations with leading CBEC platforms, including Tmall Global, JD Worldwide, Kaola, and Little Red Book (Xiaohongshu).

In China, the world’s largest e-commerce market, CBEC accounts for approximately 10% of the Chinese dietary supplement market, which is estimated to be worth between €30B and €40B overall (based on product categories classified as dietary supplements).

The products will be specifically tailored to the Asian market (packaging, dosage forms, etc.). Valbiotis has received its first order from the joint venture, with initial deliveries to Chinese consumers expected in the second half of 2026. These deliveries will be part of a commercial rollout supported by targeted marketing campaigns.

Expansion into Other Asian Markets and Initiation of Registration Procedures for Conventional Commercialization

The joint venture is also preparing to launch commercialization through the CBEC channel in other key Asian markets, starting with Vietnam, Indonesia, Japan, and Taiwan.

At the same time, the process of registering ValbiotisPRO® products in China for commercialization through "traditional" distribution channels has been initiated.

Shareholder Benefit

20% discount on ValbiotisPRO® and ValbiotisPLUS® products, granted by customer service
(service-client@valbiotis.com) upon presentation of proof of ownership of at least 85 shares                    

Terms and Conditions: Click here

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label.  Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial communication / Seitosei.Actifin 

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / LJ Com by JIN

Valentine Martin

+33 6 32 29 43 82
v.martin@ljcom.net

Name: Valbiotis
ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.